Every growth-stage telehealth company eventually opens the map of Europe. Investors ask about it in board meetings; founders sketch it into Series B decks. And the first practical question is always the same: do we land in the UK, or somewhere in the EU? The honest answer is that these are not one market with two doors — they are two very different regulatory and commercial propositions, and the sequencing decision shapes everything from entity structure to hiring. This is the operator's view of that decision, written from inside UK and EU pharmacy infrastructure.
The 'European market' is a myth — plan for two
US and international operators often model 'Europe' as a single expansion line. Operationally it splits into two very different projects. The UK is a single regulatory territory: one medical regulator (the GMC), one pharmacy regulator (the GPhC), one medicines agency (the MHRA), one clinical services inspectorate in England (the CQC), and one data protection regime (UK GDPR, enforced by the ICO). Build a compliant UK operation and it serves the whole country.
The EU is the opposite. Medicines legislation is harmonised at the top through the EMA, but telehealth practice, pharmacy ownership, e-prescription systems and online dispensing rules are set nation by nation. A model that is routine in one member state can be restricted or effectively impossible in a neighbouring one. There is no single 'EU telehealth licence' — there are 27 national conversations.
The case for landing in the UK first
Four things make the UK the default first stop for international telehealth operators, and none of them is sentimentality about the language.
- One regulatory stack, learned once. Instead of 50 state boards or 27 member states, you map your model onto a single set of national regulators. The rules are strict but public, stable and navigable.
- A mature private-pay market. The NHS anchors healthcare, but UK patients increasingly pay privately for weight management, men's and women's health, dermatology and hormone care — exactly the categories international D2C brands already run.
- English-language operations. Your questionnaires, marketing, CRM flows and support playbooks translate with editing, not rebuilding.
- Infrastructure you can rent. The UK has developed a white-label layer — prescribers, pharmacy, portals — that lets a foreign brand launch without building a regulated entity stack from scratch. We covered the build-versus-partner economics in Build vs partner for UK pharma infrastructure.
The UK also functions as a proof-of-concept market for the rest of Europe: if your funnel economics survive contact with UK acquisition costs and UK clinical governance, you have evidence the model travels outside your home market.
Key takeaway: treat the UK and the EU as two different expansion projects. The UK gives an English-language, single-regulator market you can enter in weeks on existing infrastructure; the EU gives scale you unlock country by country afterwards. Sequencing beats simultaneity.
The case for the EU — and why it is usually the second step
The EU's appeal is scale: roughly 450 million people, rising private digital-health spend, and categories that remain under-served in many member states. For some businesses — software-only models, device companies, B2B platforms — an EU-first entry through a single friendly member state makes sense.
For prescribing-and-dispensing telehealth, the calculus is different. Each target country brings its own rules on remote prescribing, its own e-prescription infrastructure, its own pharmacy ownership and dispensing restrictions, and its own language for every clinical questionnaire and patient interaction. That multiplies clinical governance work, localisation cost and regulatory risk before the first patient is treated. In our observation, operators who go EU-first without European experience spend their first year on regulatory mapping rather than growth.
What EU fragmentation means in practice
Concretely, an EU prescribing-and-shipping model has to answer, per country: Is asynchronous, questionnaire-led prescribing permitted, and for which categories? Can a prescription issued in one member state be dispensed in another under the cross-border care rules, and does the destination country's pharmacy law allow medicines to be posted to patients at all? Which entity needs to hold the pharmacy relationship, and can a non-pharmacist own it? What consent, language and labelling requirements apply?
None of these questions is unanswerable — but each is answered differently in Germany, France, Spain, the Netherlands and Poland. The practical pattern that works is a beachhead: pick one or two launch countries where the model is clearly lawful, run them properly, and expand country by country — rather than pretending the EU is one switch to flip.
The sequencing that works: UK base, EU beachhead
The pattern we see succeed looks like this. First, launch in the UK — full clinical pathway, UK entity or a white-label partner carrying the regulated layer, real patients, real unit economics. Second, once the UK operation is stable, open an EU entity to anchor European operations — an Estonian OÜ is a common, administratively light choice for a holding and operating entity (PExpo's own EU operations run through PEXPO EU OÜ in Tallinn). Third, add EU countries deliberately, in the order your category's regulation and demand justify — not in the order the map suggests.
This sequencing also matches how platforms can support you: PExpo, for example, runs UK dispensing and white-label telehealth as the core, with EU operations under the same contract — so the UK launch and the later EU expansion sit on one infrastructure rather than two vendor stacks. The mechanics of multi-region operation are covered in Taking a UK telehealth brand into the US and EU — the same logic applies in reverse.
Boards don't fund 'Europe'. They fund a first market with knowable costs and a credible path to the next one — and that first market is usually the UK.
Comparing the economics honestly
A fair UK-vs-EU comparison for a prescribing telehealth model weighs at least five lines: regulatory setup cost (one stack versus per-country mapping), time to first patient (weeks on UK white-label infrastructure versus months per EU market), localisation cost (English editing versus full translation and clinical re-review), acquisition economics (UK paid channels are competitive but liquid and measurable; EU costs vary sharply by country and category), and clinical operations (one UK governance framework versus parallel national frameworks with local clinicians).
The UK is not the cheap option in absolute terms — clinical governance, GPhC-aligned dispensing and ASA-compliant marketing all cost real money. It is the legible option: the costs are knowable in advance, which is what boards and investors actually need for an expansion decision.
A decision checklist for the board deck
If you are putting this decision in front of a board or investment committee, these are the questions that decide it:
- Is your category prescribable remotely in the UK? Weight management, men's health, women's health, dermatology and hair loss generally are, under prescriber discretion. Controlled-drug categories carry much heavier restrictions.
- Does your model depend on owning the pharmacy? If not, UK white-label infrastructure removes most of the entry cost. If yes, budget for a much longer UK build — and an even longer EU one.
- Can your funnel afford UK acquisition costs? Model UK CAC from your existing economics before committing; the UK rewards brands with strong retention, not cheap first orders.
- Do you have EU-specific demand evidence? If a single EU country is disproportionately pulling your product, a beachhead there may outrank the UK — evidence beats defaults.
- Who carries the regulated layer? Decide early whether you build entities and licences yourself or launch on a partner's infrastructure and revisit ownership at scale.
The decision is rarely UK or EU — it is UK then EU, unless your demand evidence says otherwise. What matters is entering the first market properly: real clinical governance, compliant marketing, and infrastructure that will still fit when the second and third markets arrive. That is the difference between an expansion strategy and an expensive experiment — and it is exactly the gap UK white-label infrastructure exists to close.
Frequently asked questions
Should a telehealth company expand to the UK or the EU first?
For prescribing-and-dispensing telehealth, the UK is usually the better first European market: one national regulatory stack (GMC, GPhC, MHRA, CQC, ICO), English-language operations, a mature private-pay market, and white-label infrastructure that supports launching in weeks. The EU offers larger scale but fragments into 27 national regimes, so it is typically entered country by country from an established base.
Is there a single licence to run telehealth across the EU?
No. Medicines regulation is partially harmonised through the EMA, but remote prescribing rules, e-prescription systems, pharmacy ownership and online dispensing law are set by each member state. An EU expansion is a sequence of national launches, not one approval.
Can an international company launch UK telehealth without building its own regulated entities?
Yes. White-label platforms provide the UK prescriber network, GPhC-registered dispensing and branded patient portal, so the international brand runs marketing and the patient relationship while the platform carries the regulated layer. This typically reduces UK time-to-launch from many months to a few weeks.
